BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care ConferenceFormat: ...

Core Viewpoint - Elicio Therapeutics (ELTX) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is expected to influence its stock price favorably [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The recent upgrade reflects an improvement in Elicio Therapeutics' earnings outlook, which is likely to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to determine fair value [5]. - Rising earnings estimates for Elicio Therapeutics indicate an improvement in its underlying business, which should lead to higher stock prices as investors respond to this trend [6]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - Elicio Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11]. Earnings Estimate Details - Elicio Therapeutics is projected to earn -$2.54 per share for the fiscal year ending December 2025, with no year-over-year change [9]. - Over the past three months, the Zacks Consensus Estimate for the company has increased by 5.6%, indicating a positive trend in earnings expectations [9].

Core Insights - Elicio Therapeutics has reported promising results from the Phase 2 AMPLIFY-7P trial, indicating that ELI-002 7P can induce antigen spreading in a majority of patients, enhancing immune responses against non-mKRAS neoantigens [1][5] Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, particularly targeting high-prevalence cancers like mKRAS-positive pancreatic and colorectal cancers [6] - The company utilizes its proprietary Amphiphile (AMP) technology to enhance the activation and amplification of cancer-specific T cells, aiming for durable cancer immunosurveillance [6][9] Clinical Trial Results - In the ongoing Phase 2 AMPLIFY-7P trial, 87% (13 out of 15) of evaluated patients exhibited significant T cell responses to non-mKRAS tumor neoantigens, indicating a broadening of the immune response beyond the targeted antigens [3][5] - The median fold change in T cell response over baseline for the Phase 2 trial was reported at 10.6x, demonstrating a robust immune response [3] - The trial included 90 evaluable patients, with 15 selected for antigen spreading analysis based on sufficient blood samples and tumor sequencing data [3] Product Candidate Details - ELI-002 is an off-the-shelf immunotherapy candidate targeting common KRAS mutations, which are implicated in approximately 25% of all solid tumors [6][7] - The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations, thereby increasing the potential patient population [8] Future Directions - Elicio plans to expand the application of ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers, building on the clinical successes in personalized cancer immunotherapy [6][12]

Core Insights - Elicio Therapeutics has appointed Marc J. Wolfgang as Chief Technology Officer, bringing over 30 years of biopharmaceutical leadership experience [1][2][3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance cancer-specific T cell responses, promoting durable cancer immunosurveillance [4] - Elicio's lead program, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors and is currently in a randomized clinical trial for mKRAS-positive pancreatic cancer [4] Leadership and Expertise - Marc J. Wolfgang has extensive experience in manufacturing, CMC strategy, and operations across various modalities, including cell therapy and RNA-based medicines [2][3] - His previous roles include Senior Vice President at Sail Biomedicines and Vice President of U.S. Manufacturing at BioNTech, where he oversaw critical manufacturing and supply chain operations [2] Strategic Goals - The company is preparing for late-stage development and commercial-scale execution of ELI-002, with a primary disease-free survival analysis expected in the first half of 2026 [3] - Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer, and is developing additional off-the-shelf immunotherapy candidates targeting BRAF-driven cancers and p53 hotspot mutations [4]

Financial Performance - As of September 30, 2025, Elicio Therapeutics reported total assets of $28,284,000, an increase from $28,178,000 as of December 31, 2024[19] - The company’s cash and cash equivalents increased to $20,611,000 from $17,618,000, reflecting a growth of approximately 16.9%[19] - Total operating expenses for the three months ended September 30, 2025, were $8,045,000, a decrease of 22.1% compared to $10,344,000 for the same period in 2024[21] - The net loss for the three months ended September 30, 2025, was $10,083,000, compared to a net loss of $18,838,000 for the same period in 2024, representing a reduction of 46.6%[21] - For the nine months ended September 30, 2025, the company reported a net loss of $31.85 million, an improvement from a net loss of $37.89 million for the same period in 2024, representing a decrease of approximately 15.4%[29] - The net loss for the nine months ended September 30, 2025 was $31.9 million, a 16% improvement from a net loss of $37.9 million in the same period of 2024[142] Expenses and Liabilities - Total operating expenses for the three months ended September 30, 2025, were $8,045,000, a decrease of 22.1% compared to $10,344,000 for the same period in 2024[21] - Research and development expenses decreased to $5,039,000 for the three months ended September 30, 2025, down 30.1% from $7,208,000 in the prior year[21] - The company’s total liabilities decreased significantly to $24,468,000 from $39,490,000, indicating a reduction of approximately 38.1%[19] - Total accrued expenses decreased from $8.415 million on December 31, 2024, to $5.213 million on September 30, 2025[53] - Research and development expenses for the nine months ended September 30, 2025, totaled $20.7 million, compared to $24.0 million for the same period in 2024, indicating a decrease of 13.8%[114] Cash Flow and Financing - The company had cash and cash equivalents of $20.61 million as of September 30, 2025, compared to $26.02 million at the end of 2024, indicating a decrease of about 20.8%[33] - Net cash used in operating activities for the nine months ended September 30, 2025, was $30.16 million, slightly higher than $28.32 million for the same period in 2024[29] - The company generated net cash provided by financing activities of $31.83 million for the nine months ended September 30, 2025, compared to $42.09 million for the same period in 2024, a decrease of approximately 24.4%[29] - The company plans to address its liquidity concerns through potential public offerings, private placements, and strategic partnerships, although there is no assurance these plans will be successful[33] - The company expects to incur substantial expenditures for the development of its product candidates, necessitating additional financing in the foreseeable future[33] Stock and Equity - The weighted average common shares outstanding for the three months ended September 30, 2025, were 16,692,476, an increase from 13,582,345 in the prior year[21] - Elicio Therapeutics issued 1,261,830 shares of common stock from the January 2025 Offering, net of issuance costs of $0.8 million[24] - The Company raised approximately $11.4 million in net proceeds from the 2024 ATM Program by selling 1,176,449 shares at a weighted average price of $9.68 per share[60] - The January 2025 Offering resulted in net proceeds of $9.2 million after deducting fees, selling 1,261,830 shares at a combined offering price of $7.925[64] - As of September 30, 2025, there were 806,700 shares of common stock available for issuance under the Company's equity incentive plans[66] Legal and Compliance - The company does not believe it is currently involved in any legal proceedings that would have a material adverse effect on its business[169] - There have been no material changes in the company's risk factors from those described in the Form 10-K[171] - The company has not engaged in any unregistered sales of equity securities during the reporting period[172] - The company has not defaulted on any senior securities[173] Future Outlook - Cash on hand is projected to fund operations through the second quarter of 2026, but there is substantial doubt about the company's ability to continue as a going concern[122] - The company expects its cash and cash equivalents to be sufficient to fund operations through the second quarter of 2026, but may require additional financing[154] - The company plans to address its funding needs through the sale of common stock or other securities, debt financings, or strategic partnerships[156] - The company achieved a milestone related to ongoing clinical trials, recording a license expense of $0.4 million during the nine months ended September 30, 2024[86] Internal Controls and Governance - As of September 30, 2025, the company's disclosure controls and procedures were evaluated as effective by the management team[166] - There were no changes in the internal control over financial reporting during the quarter ended September 30, 2025, that materially affected the internal control[167] - The company continues to take advantage of exemptions from certain disclosure requirements as a smaller reporting company[162]

Core Insights - Elicio Therapeutics reported encouraging results from its Phase 2 AMPLIFY-7P study, indicating fewer disease progressions and deaths than projected, which may positively impact disease-free survival (DFS) [2][5] - The company updated its guidance for the DFS analysis to the first half of 2026 and believes its current cash position will support operations through this critical period [2][9] Recent Highlights - Elicio presented updated data showing that ELI-002 7P induced mutant KRAS-specific T cell responses in 99% of evaluable patients, with an 86% antigen response rate [6] - The company announced a planned investigator-initiated Phase 1 trial of ELI-002 7P in collaboration with Memorial Sloan Kettering Cancer Center, expected to begin in the first half of 2026 [6] - The Independent Data Monitoring Committee recommended continuing the Phase 2 study without modifications, confirming a favorable safety profile for ELI-002 7P [6] Financial Results - R&D expenses for Q3 2025 were $5.0 million, down from $7.2 million in Q3 2024, primarily due to reduced clinical trial costs [5][10] - General and administrative expenses decreased slightly to $3.0 million from $3.1 million year-over-year [7][10] - The net loss for Q3 2025 was $10.1 million, significantly lower than the $18.8 million loss in Q3 2024, with a net loss per share of $0.60 compared to $1.39 [8][10] Cash Position - As of September 30, 2025, Elicio had cash and cash equivalents of $20.6 million, which is expected to support operations through Q2 2026 [8][11][9] - The company raised approximately $11.1 million in gross proceeds since the beginning of Q3 2025, extending its cash runway [5][9] Future Plans - Elicio plans to request an End of Phase 2 meeting with the FDA to finalize the Phase 3 trial design for ELI-002 7P following the DFS analysis [4] - The company aims to expand ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers [12][14]

Core Insights - Elicio Therapeutics (ELTX) has been recognized for its promising development of a vaccine targeting KRAS, a significant area in cancer research [1] Company Overview - Elicio Therapeutics has been under observation for approximately five years due to its advancements in vaccine development [1] - The company focuses on the scientific aspects of biotechnology and aims to educate investors about the underlying science [1] Industry Context - The development of vaccines targeting KRAS is crucial in the biotechnology sector, particularly in cancer treatment [1]

Core Insights - Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director, enhancing its board with experienced professionals to facilitate U.S. market access and strategic growth [1][3] - Alling brings over 30 years of experience in corporate banking and capital markets, managing a multi-billion-dollar portfolio and specializing in M&A, IPOs, and revenue optimization [2] - The company aims to become a key player in the barium and iodine contrast markets by vertically integrating its operations and producing its own Active Pharmaceutical Ingredients (API) [5][8] Company Strategy - Voyageur is focused on developing high-performance and cost-effective imaging contrast agents, with a strategic plan to partner with established GMP pharmaceutical manufacturers for product validation [6] - The company owns a 100% interest in the Frances Creek barium sulphate project, which is expected to provide a superior quality product compared to current synthetic alternatives [7] - Voyageur's vision includes becoming the first vertically integrated company in the radiology contrast media market, ensuring quality and cost efficiency through control of all primary input costs [8]

Core Insights - Giant Mining Corp. has expanded its engagement with RESPEC Company LLC to incorporate silver assays from recent and historic drilling at the Majuba Hill project, enhancing the project's potential [1][2][3] Engagement Purpose - RESPEC's updated interpretation will include results from the latest drill program, specifically core data from drill holes MHB-30 through MHB-36 [2] - The integration of silver assays will refine the geological model, evaluate new findings' impact on project potential, and guide further drilling strategies [3] Project Highlights - Majuba Hill has previously reported high-grade silver intercepts, including 74.0 feet of 30.1 g/t Ag, emphasizing its polymetallic strength and potential for significant by-product value [4] - The project is located in Nevada, a top-ranked mining jurisdiction, covering 9,684 acres with existing infrastructure that provides cost advantages [7][9] Strategic Impact - The updated interpretation will strengthen the technical foundation for future economic potential and highlight new target zones, aligning with U.S. demand for secure supply chains [7] - The U.S. Geological Survey's recent designation of copper and silver as critical minerals underscores the strategic relevance of Majuba Hill's mineral system [6][7] Market Awareness - The company has entered into a consulting agreement with Plutus Invest & Consulting GmbH for marketing and investor awareness in the European market, with a total payment of EURO 120,000 [12] Company Overview - Giant Mining is focused on advancing late-stage copper and copper/silver/gold projects to meet the growing global demand for critical metals, driven by initiatives like the Green New Deal [13][14] - The Majuba Hill project is positioned to become a significant copper deposit, essential for meeting increasing demand [15]

Core Insights - Elicio Therapeutics announced new immunogenicity data from the Phase 2 AMPLIFY-7P trial for ELI-002 7P, showing strong T cell responses in patients with mKRAS pancreatic ductal adenocarcinoma [1][3][6] - The company also presented preclinical data for ELI-004, indicating over 90% tumor eradication in advanced solid tumors [1][8] Group 1: ELI-002 7P Immunogenicity Data - In the AMPLIFY-7P trial, 99% of 90 evaluable patients achieved robust mKRAS-specific T cell responses, with a mean increase of 145-fold over baseline [4][6] - 85% of patients exhibited combined CD4 and CD8 T cell activation, correlating with clinical activity [4][6] - 88% of patients generated responses to their own tumor-specific mutations, indicating personalized immune activation [4][6] Group 2: ELI-004 Preclinical Data - ELI-004 demonstrated complete tumor eradication in over 90% of cases in preclinical studies, with long-term protection against recurrence [3][8] - The efficacy of ELI-004 was linked to the presence of CD8 T cells and effective lymphocyte trafficking from lymph nodes [8] - This approach suggests a promising off-the-shelf strategy for solid tumor immunotherapy [8] Group 3: Presentation Details - The findings will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting [2] - The late-breaking abstract for ELI-002 7P highlights its potential to induce robust T cell immunity across diverse HLA backgrounds [6][7] Group 4: Company Overview - Elicio Therapeutics focuses on developing novel immunotherapies targeting high-prevalence cancers, particularly those driven by KRAS mutations [14] - The company's AMP platform aims to enhance immune responses by delivering therapeutics directly to lymph nodes [12][13] - Elicio plans to expand its pipeline to include additional indications for ELI-002 and other candidates targeting different mutations [14]